Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals reported $6.46M in Stock for its fiscal quarter ending in March of 2023. Data for Intercept Pharmaceuticals | ICPT - Stock including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals reported $185K in Cost of Sales for its fiscal quarter ending in June of 2023. Data for Intercept Pharmaceuticals | ICPT - Cost Of Sales including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals reported $-7029000 in EBITDA for its fiscal quarter ending in June of 2023. Data for Intercept Pharmaceuticals | ICPT - Ebitda including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals reported $67.55M in Equity Capital and Reserves for its fiscal quarter ending in June of 2023. Data for Intercept Pharmaceuticals | ICPT - Equity Capital And Reserves including historical, tables and charts were last updated by Trading Economics this last February in 2025.
https://www.datainsightsmarket.com/privacy-policyhttps://www.datainsightsmarket.com/privacy-policy
The market for bile duct cancer therapeutics is projected to reach USD 3,451.6 million by 2033, exhibiting a CAGR of 13.4% during the forecast period. The increasing prevalence of bile duct cancer, coupled with the availability of advanced treatment options, is driving the growth of the market. Technological advancements, such as the development of targeted therapies and immunotherapy, are also contributing to the expansion of the market. Key players in the bile duct cancer therapeutics market include Pfizer, F. Hoffmann-La Roche, Bristol-Myers Squibb, Teva Pharmaceutical, Eli Lilly and Company, Sanofi, Fresenius Kabi, Mylan, Delcath Systems, Accord Healthcare, Intercept Pharmaceuticals, and Celgene. These companies are engaged in research and development, manufacturing, marketing, and distribution of bile duct cancer therapeutics. The market is highly competitive, with companies adopting various strategies such as mergers and acquisitions, collaborations, and licensing agreements to gain market share.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals 株式 - 現在の値は、過去のデータ、予測、統計、チャートや経済カレンダー - Mar 2025.Data for Intercept Pharmaceuticals | 株式 including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals reported $187.02M in Current Liabilities for its fiscal quarter ending in June of 2023. Data for Intercept Pharmaceuticals | ICPT - Current Liabilities including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals Ação - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Mar 2025.Data for Intercept Pharmaceuticals | Ação including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals reported $29.79M in Trade Debtors for its fiscal quarter ending in June of 2023. Data for Intercept Pharmaceuticals | ICPT - Trade Debtors including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals سهم - القيم الحالية، والبيانات التاريخية، والتنبؤات والإحصاءات والرسوم البيانية والتقويم الاقتصادي - Mar 2025.Data for Intercept Pharmaceuticals | سهم including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals 股票 - 当前值,历史数据,预测,统计,图表和经济日历 - Mar 2025.Data for Intercept Pharmaceuticals | 股票 including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals Stock - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.Data for Intercept Pharmaceuticals | Stock including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals Készlet - Az oldal aktuális és múlbeli adatokat, elorejelzéseket, statisztikákat, grafikonokat és a gazdasági naptár adatait tartalmazza - Mar 2025.Data for Intercept Pharmaceuticals | Készlet including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals Action - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.Data for Intercept Pharmaceuticals | Action including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals Aktier - Aktuella värden, historiska data, prognoser, statistik, diagram och ekonomisk kalender - Mar 2025.Data for Intercept Pharmaceuticals | Aktier including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals Azione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.Data for Intercept Pharmaceuticals | Azione including historical, tables and charts were last updated by Trading Economics this last March in 2025.
Not seeing a result you expected?
Learn how you can add new datasets to our index.
Attribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Intercept Pharmaceuticals reported $6.46M in Stock for its fiscal quarter ending in March of 2023. Data for Intercept Pharmaceuticals | ICPT - Stock including historical, tables and charts were last updated by Trading Economics this last March in 2025.